News coverage about Paratek Pharmaceuticals (NASDAQ:TSPT) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.1604715437521 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-paratek-pharmaceuticals-tspt-share-price/1608608.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:TSPT)

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.